CannaPharmaRx 3Q 2026: Revenue $137.71K, EPS ($0.00) — 10-Q Summary
CannaPharmaRx reported 3Q 2026 revenue of $137.71K, down 79% YoY, with net income of $645.42K, reversing a prior loss. Lower sales volumes, including no Cantek sales, drove revenue decline, while non-cash gains improved earnings. The company has $32,037 in cash and a $30.93M working-capital deficiency, with management expressing doubt about its ability to continue operations.
